BioSpace News Archive

In connection with the offering, the Company will issue 484,848 registered ADSs at a purchase price of $8.25 per ADS in a registered direct offering.

Tetra Bio-Pharma announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

This label expansion is the first for electroCore since gammaCore received its initial FDA clearance.

In reaching its conclusion, ISS performed a detailed review of both sides’ positions in the election contest as well as its own thorough independent analysis.

Dr. Plotkin joins Ritter Pharmaceuticals with nearly thirty years of experience in strategic, global clinical pharmaceutical research involving all phases of drug development.

The Company anticipates the readout of the interim analysis in mid-2018, and the availability of top-line data from the full study toward the end of 2018.

The white paper can be found in the Research and White Papers section of PositiveID’s website.

The 100-patient study that appeared in the December 2017 ASJ demonstrated high patient satisfaction with Silhouette InstaLift for lifting of the mid-face while improving a number of age related changes.

Studies over the past decade have demonstrated that there is a dynamic interaction between a patient’s immune system and the existence of a tumor.

Otsuka announce that the latter has been awarded a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of Otsuka’s investigational compound to treat tuberculosis (TB), OPC-167832, in combination with delamanid as the backbone of a pan-TB regimen in line with the World Health Organization’s (WHO) Target Regimen Profiles (TRP).